ACHE and early-onset autosomal dominant Alzheimer disease: Additionally, its potential utilization in treating Alzheimer’s disease, a neuroinflammatory disease, was demonstrated with a half-maximal inhibitory concentration (IC50) of 4.51 ± 0.03 μM on acetylcholinesterase (AChE), which is a cholinergic enzyme in the nervous system [14].